Gyre Therapeutics stock
GYRENASDAQGyre Therapeutics, Inc., HealthcareISIN US4037831033
35Score 35 out of 100, Weak
Price and trend
31 / 100
Price history
−47% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 38% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 51% below its 52-week high. Largest decline in 20 years: 100% (March 2011 to March 2023).
Chart figures for advanced users
- SMA 50$6.38
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.85
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.01
- The lowest closing price of the last twelve months.
- Resistance$8.76
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Gyre Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $451.7M, is number 255 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $116.59M (up 10.2% year on year) and earnings of $5.03M (down 58.4%).
- MEQIRI Score 35 out of 100 (Weak): rank 637 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 41% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $74.8M, financial debt $3.42M.Stability 77
Weaknesses
- DilutionShare count up 366% since 2020.Capital allocation 9
- Loss-makingLoss of $25M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$180K over the last 12 months.Fundamentals 17
Its standout strengths are stability and growth, while momentum and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.5% on the twelve months before. Revenue has grown strongly since 2020, at around 41% per year. From 2020 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 95%, operating 10%, net 4%. Last 12 months: net −21%. From 2020 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Mar 2027in 119 days
- Last reported
- 5 Nov 2026EPS reported −$0.04 (expected −$0.15)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.400.0%
- Revenue
- $109.5M0.0%
- Earnings per share
- −$0.240.0%
- Revenue
- $139.6M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $812,138 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ye WeiguoSale
18 Jun 2026, Chief Operating Officer
- Shares
- 3,000
- Price
- $6.35
- Value
- $19,050
- Ye WeiguoSale
11 Jun 2026, Chief Operating Officer
- Shares
- 2,800
- Price
- $6.17
- Value
- $17,276
- Ye WeiguoSale
10 Jun 2026, Chief Operating Officer
- Shares
- 5,000
- Price
- $6.24
- Value
- $31,200
Show 12 more
- Ye WeiguoSale
10 Jun 2026, Chief Operating Officer
- Shares
- 6,418
- Price
- $6.21
- Value
- $39,856
- Ye WeiguoSale
9 Jun 2026, Chief Operating Officer
- Shares
- 3,000
- Price
- $6.15
- Value
- $18,450
- Ye WeiguoSale
9 Jun 2026, Chief Operating Officer
- Shares
- 14,500
- Price
- $6.14
- Value
- $89,030
- Ye WeiguoSale
5 Jun 2026, Chief Operating Officer
- Shares
- 15,401
- Price
- $6.40
- Value
- $98,566
- Ye WeiguoSale
4 Jun 2026, Chief Operating Officer
- Shares
- 19,575
- Price
- $6.13
- Value
- $119,995
- Ye WeiguoSale
26 May 2026, Chief Operating Officer
- Shares
- 4,000
- Price
- $6.10
- Value
- $24,400
- Ye WeiguoSale
22 May 2026, Chief Operating Officer
- Shares
- 3,500
- Price
- $6.08
- Value
- $21,280
- Ye WeiguoSale
21 May 2026, Chief Operating Officer
- Shares
- 12,820
- Price
- $6.15
- Value
- $78,843
- Ye WeiguoSale
19 May 2026, Chief Operating Officer
- Shares
- 9,120
- Price
- $6.37
- Value
- $58,094
- Ye WeiguoSale
18 May 2026, Chief Operating Officer
- Shares
- 200
- Price
- $6.62
- Value
- $1,324
- Ye WeiguoSale
15 May 2026, Chief Operating Officer
- Shares
- 13,100
- Price
- $6.65
- Value
- $87,115
- Ye WeiguoSale
14 May 2026, Chief Operating Officer
- Shares
- 15,580
- Price
- $6.91
- Value
- $107,658
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Gyre Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Hansa BiopharmaHNSA.ST $458.62M47
- Assembly BiosciencesASMB $455.47M33
- ArvinasARVN $452.5M37
- AgenusAGEN $452.32M49
- ProthenaPRTA $448.28M43
- Benitec BiopharmaBNTC $440.91M31
- YD BioYDES $435.61M40
- Tectonic TherapeuticTECX $429.3M34
ETFs that hold Gyre Therapeutics
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.00% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.